-
Product Insights
New![]()
Net Present Value Model: Valneva SE’s VLA-1553
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Profile
![]()
Valneva SE – Company Profile
Valneva SE (Valneva) is a biotechnology company that develops life-saving vaccines against infectious diseases and cancer. The company's products include a vaccine indicated for the prevention of Japanese encephalitis and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of Lyme disease, Zika virus, Chikungunya and infections caused by Clostridium difficile. The company works in partnership with various pharmaceutical and biopharmaceutical companies to develop its pipeline vaccine candidates and distribute its...
Add to Basket -
Product Insights
New![]()
Net Present Value Model: IGM Biosciences Inc’s IGM-8444
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VLA-1553 in Chikungunya Fever
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VLA-1553 in Chikungunya FeverDrug Details:VLA-1553 is under development for the prevention of chikungunya. It is administered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MBF-015 in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MBF-015 in Parkinson's DiseaseDrug Details:MBF-015 is under development for the treatment of synaptopathies (huntington disease, alzheimer's...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Racemetyrosine in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Racemetyrosine in Ewing Sarcoma Drug Details: Racemetyrosine (SM-88) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Avibactam Tomilopil + Ceftibuten) in Urinary Tract Infections
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Avibactam Tomilopil + Ceftibuten) in Urinary Tract Infections Drug Details: (avibactam tomilopil + ceftibuten)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VLA-15 in Lyme Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VLA-15 in Lyme Disease Drug Details: VLA-15 (IC-15) is under development for the prevention...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6330 in Ovarian Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6330 in Ovarian Cancer Drug Details: GDC-6036 (RG6330) is under development for the...
-
Track & Monitor
New![]()
Innovation in pharma: attenuated virus vaccines
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s attenuated virus vaccines innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and experience...
-
Sector Analysis
NewCOVID-19 Vaccines Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2026
COVID-19 Vaccines Market Report Overview The sales of COVID-19 vaccines across the 7MM reached $25 billion in 2021 and consisted of Tour authorized products: Comirnaty, Spikevax, Vaxzevria, and Jcovden. the COVID-19 vaccines market declined across the 7MM in 2022 as most individuals completed primary vaccinations and received at least one dose of an updated bivalent mRNA booster vaccine. Overall, the COVID-19 vaccines market is expected to significantly decline across the 7MM during the forecast period, at a negative compound annual...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022
COVID-19 Analyst Consensus Sales Report Overview Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within...
-
Product Insights
![]()
Net Present Value Model: VLA-1553
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model VLA-1553 Drug Details VLA-1553 is under...
-
Product Insights
![]()
Net Present Value Model: Ixiaro
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Ixiaro Drug Details Japanese encephalitis virus...
-
Product Insights
![]()
Net Present Value Model: Dukoral
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Dukoral Drug Details Cholera Vaccine (Dukoral)...
-
Product Insights
![]()
Net Present Value Model: VLA-2001
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model VLA-2001 Drug Details Coronavirus Disease 2019...
-
Track & Monitor
![]()
Innovation in Pharmaceuticals: Anti-viral antigen-based compositions
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Track & Monitor
![]()
Innovation in Pharmaceuticals: Flavivirus vaccine components
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Track & Monitor
![]()
Innovation in Pharmaceuticals: HBV (Hepatitis B Virus) peptides
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – VLA-1553
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry VLA-1553 Drug Details VLA-1553 is under development for the prevention of chikungunya. It is...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.